

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
July 23, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report  
(Date of earliest event reported):

July 23, 2003

ANTIGENICS INC.  
(Exact name of registrant as specified in its charter)

DELAWARE	000-29089	06-1562417
(State or other jurisdiction of incorporation of organization)	(Commission file number)	(I.R.S. Employer Identification No.)

630 FIFTH AVENUE, SUITE 2100  
NEW YORK, NEW YORK 10111  
(Address of principal executive offices and zip code)

(212) 994-8200  
(Registrant's telephone number, including area code)

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(c) Exhibits:

99.1 Press Release dated July 23, 2003

Item 9. Regulation FD Disclosure (Information furnished pursuant to Item 12, "Disclosure of Results of Operations and Financial Condition").

On July 23, 2003, Antigenics Inc. announced its financial results for the quarter ended June 30, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this current report on Form 8-K.

The information in this report on Form 8-K and the Exhibit attached hereto is being furnished pursuant to Item 12 of Form

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

8-K, Disclosure of Results of Operations and Financial Condition, and is presented under Item 9, Regulation FD Disclosure, in accordance with the procedural guidance in SEC Release No. 33-8216. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: July 23, 2003

By: /s/ Garo H. Armen

-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

The following designated exhibits are filed herewith:

Exhibits:

99.1 Press Release dated July 23, 2003